Zydus Lifesciences Walk-In Interview 2025: Zydus Lifesciences Limited is hiring for its Topical Ointment (Non-Sterile Formulation) plant in Ahmedabad. Walk-in interview on 9th November 2025 at Vapi for Production, Quality Control, Quality Assurance, and Technical Assistant positions. Apply now! 1. About Zydus Lifesciences Limited Zydus Lifesciences Limited (formerly known as Cadila Healthcare) is one of India’s leading pharmaceutical companies, dedicated to delivering high-quality healthcare solutions.

Stocks to watch: Shares of firms like Adani Green, Kalyan Jewellers, ONGC, Zydus Lifesciences, Aster DM, and others will be in focus on Tuesday's trade

Zydus Lifesciences Walk-In Interview 2025 – Explore pharma jobs in Ahmedabad for Production, Filling & Packing, and Quality Control (Analyst) roles. Apply now to join India’s leading pharmaceutical company. Are you looking for rewarding pharma jobs in Ahmedabad? Here’s an exciting opportunity! Zydus Lifesciences Limited is conducting a Walk-In Interview in Ahmedabad on 5th October 2025 for its Topical Ointment Formulation Plant.

Zydus Lifesciences Walk-in Interview 2025 conducting a walk-in interview on 21st September 2025 in Ahmedabad for IT CSV Engineers (Executive–Assistant Manager) with 3–6 years of experience. Explore pharma IT career opportunities at Zydus in Ahmedabad and Ankleshwar. 1. Introduction Zydus Lifesciences Limited, one of India’s leading pharmaceutical companies, is inviting talented professionals to join its growing IT department. If you are an experienced IT CSV Engineer looking to advance your career in the pharma industry, this is the opportunity you’ve been waiting for.

"Zydus Lifesciences Walk-In Interview 2025 – Pharma job openings in Ankleshwar, Gujarat. Apply for Production, GMP, Pilot Plant, and Apprentice roles. Freshers & experienced candidates can attend on 10th September 2025." Zydus Lifesciences Limited, a leading pharmaceutical company in India, has announced exciting job openings in Ankleshwar, Gujarat for its API Manufacturing Plant, Unit-2. This is a great opportunity for freshers as well as experienced candidates to build their careers with one of the most reputed pharma companies in India.

Walk-In Interview Zydus Lifesciences Ankleshwar for freshers & experienced for API Manufacturing Plant, Ankleshwar. Walk-in interview on 3rd Sept 2025. Apply now! Are you looking for a promising career opportunity in the pharmaceutical industry? Here’s some exciting news for freshers and experienced candidates! Zydus Lifesciences Limited, one of India’s leading pharmaceutical companies, is conducting a walk-in interview at its API Manufacturing Plant, Ankleshwar (Unit-2)

Investing.com -- Agenus Inc . (NASDAQ:AGEN) stock soared 30% following the announcement of a strategic collaboration with Zydus Lifesciences, which includes a $141 million deal to advance BOT/BAL and expand Zydus’ biologics manufacturing in the United States. The partnership agreement, which involves exchanging Agenus’ biologics CMC facilities in California for an upfront consideration of $75 million and up to an additional $50 million in contingent payments, has been designed to accelerate the clinical development and scale global manufacturing. Zydus will also launch a BioCDMO business in the U.S. with Agenus as its first customer, ensuring the manufacturing readiness of BOT/BAL for BLA submission and potential commercial launch. Furthermore, Agenus will receive a 5% royalty on net sales from Zydus in India and Sri Lanka, where Zydus will have the exclusive license to develop and commercialize these therapies. Additionally, Zydus will make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares at $7.50 per share, totaling around $16 million. The CEO of Agenus, Dr. Garo Armen, highlighted the trade agreement between the United States and India as a positive step towards strengthening Indian-American relations and ensuring secure biopharma supply chains. He expressed confidence in the partnership’s potential to accelerate future clinical trials and expand the global oncology therapeutics footprint of BOT/BAL. Dr. Sharvil Patel, Managing Director at Zydus Lifesciences, expressed enthusiasm for the partnership, noting the potential benefits for patients in India, Sri Lanka, and globally. Zydus plans to conduct clinical trials for BOT/BAL in various stages of disease and expand its use beyond colorectal cancer to other significant diseases such as triple-negative breast cancer. The transaction is subject to customary closing conditions and due diligence, with the parties expecting to complete closing agreements within 60 days. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Orphan drug designation offers development incentives and potential market exclusivity